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Abstract
The human body has natural systems for vasodilation which are fueled by nitric oxide
production, but in cases of cardiac disfunction and stress nitric oxide can be inhibited. In this
study, nitric oxide was studied as a mediator for the blood rush experienced from the warming
after induced hypothermia. Nitric oxide (NO) was introduced through sodium nitrate, which was
aimed to reduce the speed and turbulence of blood flow through interaction between NO and the
active site of hemoglobin. A viscometer was used to examine the rate of blood flow, while the
temperature was varied to simulate the conditions of induced hypothermia. Two temperatures
were tested to simulate the warming following induced hypothermia, and three concentrations of
sodium nitrate were added to the samples to examine the correlation between flow and
concentration. The results indicated that the 0.11 M NaNO3 expressed constant blood viscosity
for both temperatures, the 0.09 M NaNO3 exhibited some mediation, and the 0.10 M showed the
least mediation.
Therapeutic Hypothermia
Therapeutic cooling has been employed in medicine for a very long time, but with varied
results. In recent years, several studies have examined induced hypothermia as a treatment after
cardiac arrest. These studies have concluded that cooling patients slows tissue damage caused
from cardiac trauma [1,2]. Therapeutic hypothermia, however, contributes to a high mortality
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rate, and many patients who do survive the procedure are left with neurological deficits. A study
conducted at the Central Lisbon Hospital Center, in Portugal, used induced hypothermia on ICU
patients and yielded a 61% mortality rate [3]. Hemorrhage and increased blood loss were
hypothesized as possible causes for this percentage [3,4]. Another study specifically examined
blood effects from induced hypothermia in perioperative patients and indicated that blood loss
was increased by 16% [5]. The increased blood loss was likely the result of the blood rush during
the hypothermia reversal process. In several cases, it was observed that as the blood was
warmed, it reacts drastically due to blood shear thinning properties, leading to a blood rush [1,5].
This is a biological representation of the inverse relationship between viscosity and temperature,
which is foreign to the human system. The blood rush can yield brain damage and added stress to
an already pressured cardiac system. This blood rush has been noted to occur even when the
warming and cooling processes are done at a very slow rate. In each of the studies referenced,
the heating and cooling process took approximately 24 hours; however, the effects of the blood
rush were still present [3,4]. If the rush could be controlled, it might make induced hypothermia
a much more successful procedure.
Nitric Oxide
Nitric oxide (NO) plays a key physiological role in the cardiovascular, respiratory,
digestive, immune, and nervous systems [6]. NO acts as a cardiovascular stimulant which relaxes
the vessels and fuels the pacemaker [7,8, 9]. The NO molecule is produced in the endothelium of
the blood vessels from the conversion of arginine to citrulline when the cardiac system is healthy
[6]. Plaque buildup in the vessels can severely impair the ability of nitric oxide to be released [7,
10]. Since plaque is a major cause of cardiac disfunction, it is likely that many patients treated
with induced hypothermia for cardiac arrest would have plaque hindering their ability to produce
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NO [7]. For this reason, an introduction of nitric oxide into the circulatory system during the
warming process of induced hypothermia may work to normalize blood flow and contribute to
restoring the body’s natural homeostasis. As the core temperature is raised, vasodilation and
sweating are required for heat to dissipate, and the vasodilator responsible for this is NO. A study
examining the blood flow to the skin noted that nitric oxide contributes 30% of the vasodilation
reflex experienced in the body when heat is dissipated during core cooling [11]. In another study,
scientists evaluated the amount of NO required by the body to achieve normal blood flow and
discovered that patients with worse health or heart strain required more NO to propel normal
circulation [7]. Nitric oxide also has been shown to work in the prevention of plaque in the
circulatory system, which could aid in the long-term rehabilitation of cardiac arrest patients [7].
Pharmaceutical Use of Nitric Oxide
Sodium nitrate is an organic salt that is utilized in several medications to introduce nitric
oxide into the circulatory system. Nitrodilators, which contain sodium nitrate, are currently used
to relax the blood vessels of hypertensive patients [12]. Sodium nitrate itself has been used in
patients to prevent cardiac arrest [13]. Sodium nitrate dissociates in vivo to release nitric oxide,
sodium ions, and diatomic oxygen. Nitric oxide and sodium are diffused out of the bloodstream
in milliseconds; the oxygen, however, is not [14]. Oxygen remains in the blood much longer than
the nitric oxide because the NO molecule binds to the allosteric site of the heme group in
hemoglobin, reducing its ability to bind oxygen [15]. Saturating the blood with oxygen over a
long period of time can be dangerous; therefore, a sodium nitrate treatment would only need to
be used in targeted cases for short durations [15,16]. Also, in many cases, patients treated with
sodium nitrate quickly became accustomed to the treatment, and it no longer yielded an effect
[12]. Therefore, employing sodium nitrate as a long-term medication would likely be fruitless.
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Studies have not yet explored the benefits of one-time intravenous treatments with sodium nitrate
for therapeutic hypothermia. The controlled environment required for induced hypothermia
would aid in controlling the oxygen levels of the patients. This could prevent saturation, making
the introduction of sodium nitrate safer.
Experimental Development
The current uses of sodium nitrate in medicine point towards a potential application in
the blood warming process after induced hypothermia. While there are some negative
associations connecting high levels of nitrates to cancer, the NO molecule only exists in the
blood for milliseconds; therefore, the use of sodium nitrate is feasible in specialized procedures
[14, 17]. This study hypothesized that sodium nitrate would regulate human blood flow when the
blood was warmed to mitigate the blood rush and bring the flow back to normal. The experiment
was done to determine the interaction between the red blood cells (RBCs) and nitric oxide. The
effect of NO on blood flow was measured by viscosity. Blood flow was analyzed in this study
using a Zahn cup viscometer at targeted temperatures to simulate induced hypothermia.
Defibrinated sheep blood was used, and samples were tested both without sodium nitrate and
with three different concentrations of sodium nitrate.

Methodology
Defibrinated sheep blood was obtained for testing and stored at approximately 1°C.
Under these conditions, the blood has a shelf life of 28 days. The blood was defibrinated
mechanically by the manufacturer, Quad Five, and was verified for purity by the USDA [18].
Defibrinated blood is free of anticoagulants that can interfere with observation of the
experimentally-induced effects on the blood viscosity. Defibrinated sheep blood has been

Introduction of Sodium Nitrate to Affect Blood Viscosity

5

certified to be a viable substitute for human blood in diagnostic testing and is used by many
companies for experimentation [19].
The Zahn Cup viscometer, size two, was used to measure viscosity. The size two Zahn
cup has an orifice size of 0.108 inches and a capacity of 44 milliliters. This was used in the
calculation of shear rate [20]. Zahn Cup viscometers are used to measure the viscosity of a fluid
via the time of efflux through the orifice. This brand of viscometer is often used to measure the
viscosity of paint. Paint is a non-Newtonian, shear thinning, fluid similar to blood, so the Zahn
Cup viscometer should give applicable results for blood viscosity. The design of the Zahn Cup
employs gravity for viscosity measurements, an ideal aid in reducing added turbulence in the
samples [21].
The recommended temperature for use with Zahn cup viscometers is 25°C. However, a
calibration curve can also be made with a control liquid and careful monitoring of the
temperature as per the instructions of the manufacturer [20]. A calibration curve was constructed
for this experiment. Defibrinated sheep blood without sodium nitrate was the control standard.
Three trials were taken for each temperature tested, with the average being used to form the
curve. The range of temperature was set from 25°C to 37°C with trials beginning at the highest
temperature. 37°C was set as the upper bound to account for the warming to normal human body
temperature. 25°C was used for cooling and was chosen from the recommended temperatures for
the Zahn Cup viscometer, as per the manufacturer’s guide [20]. Since this temperature is five
degrees lower than the usual minimum cooling for induced hypothermia, this was assumed to
give a reasonable result for the minimum bound of the data range.
To begin, blood samples were raised from refrigeration to room temperature,
approximately 22°C. The temperature was then raised slowly to 37°C using a warm water bath

Brianna Munnich & Dr. Willa Harper

6

with temperature control. The bath was raised in increments of 5°C, allowing the blood to
acclimate to the temperature slowly. This prevented the blood from denaturing. When it reached
37°C, the first reading was measured. Readings were taken at each degree increment as the blood
was cooled to 24°C. An ice bath was used for cooling.
Readings were taken by submerging the Zahn Cup in the blood and allowing it to warm.
Once the viscometer had warmed to temperature, the cup was raised to just under the top of the
blood. The cup was then raised vertically six inches and placed on a hook set over the center of
the collection beaker. A stopwatch was started as the cup broke the surface of the blood and was
stopped when the first break in the flow of the blood was observed [20]. Between each reading,
the Zahn cup was rinsed to prevent cohesion which could alter the flow time. The Zahn cup was
cleaned completely between each sample to avoid contamination.
Sodium nitrate solutions were made by diluting the salt in water. The amount of sodium
nitrate needed was calculated using the concentration of salt administered in a typical IV bag of
sodium chloride given for dehydration [22]. The calculated concentration was 0.10 M NaNO3.
The concentrations of 0.09 M and 0.11 M NaNO3 were also tested to account for the difference
in molecular weight of sodium nitrate and sodium chloride and to account for different rates of
dissociation for each salt in the blood. Ten trials were run at each sodium nitrate concentration
for both 25°C and 37°C. The average of these ten trials, excluding major outliers, were
considered in the final analysis of viscosity. Outliers were categorized as any values which were
± 0.20 seconds away from the closest flow time.
All blood and instruments were handled using medical grade gloves and goggles. These
safety procedures ensured that the blood was not contaminated during testing, and samples were
disposed of properly using biohazard procedures. All beakers and utensils which touched blood
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were cleaned with appropriate procedures between each change of concentration and temperature
in the experiment.

Results

The results in Table 1

TABLE 1. CONTROL TEMPERATURE CURVE

show the gathered data for the
DATA FOR BLOOD WITH NO SODIUM NITRATE

control curve. From 25°C to 32°C,
TEMP.

Flow Time

DV

Shear Rate
a decreased dynamic viscosity (DV)

(°C)

(sec)

(PA∙s)

(1/s)
occurs as the temperature

25

15.18

-3

4.4 x 10

1.22
increases. From 32°C to 37°C,

26

15.10

-3

4.1 x 10

1.23
a blood rush appears with an

27

14.96

-3

3.6 x 10

1.24
increase in dynamic viscosity,

28

14.93

-3

3.5 x 10

1.24
followed by a quick reduction to

29

14.94

-3

3.5 x 10

1.24
the minimum dynamic viscosity.

-3

30

14.89

3.3 x 10

1.26

31

14.80

3.0 x 10-3

1.26

14.58

-3

Apparent Viscosity
32

2.1 x 10

1.27
The apparent viscosity is a

33

14.64

-3

2.4 x 10

1.27
comparison of the dynamic

34

14.64

-3

2.4 x 10

1.27
viscosity to the rate at which the

35

14.80

-3

2.9 x 10

1.25
fluid shears. Apparent viscosity is

36

14.77

-3

2.9 x 10

1.26
used to model non-Newtonian

37

14.60

2.2 x 10

-3

1.27
fluids which do not have a constant

shear rate. Blood is a shear-thinning fluid so it should be modeled with apparent viscosity [21].
This is because blood aggregates due to its colloidal structure. For each concentration and
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temperature tested, the apparent viscosity was tabulated and evaluated in Pascal seconds. The
ranges seen in the apparent viscosity across the trials indicate the influence of temperature on the
shear stress, which causes turbulence in the sample.

Calculation of Dynamic Viscosity
Kinematic viscosity (KV) was calculated using the formula provided with the Zahn cup
viscometer: KV=3.5 (t-14); where 3.5 and 14 are unitless constants [20]. To convert from KV,
(measured in m Pa∙s) to dynamic viscosity (DV), the kinematic viscosity was multiplied by the
density of blood (𝜌), 1.06 g/m3 [23]. Lastly, the dynamic viscosity was converted to Pa∙s for
comparison with the values of normal blood viscosity, 3.0 x 10-3 and 4.0 x 10-3[24].

Sample Calculation of Dynamic Viscosity
Calculation was done using the flow time of 15.18 seconds from the 25°C control trial.
𝐾𝑉 = 3.5 (𝑡 − 14)
𝐾𝑉 = 3.5 (15.18 − 14)

𝐾𝑉 = 4.13 mPa ∙ s

𝐷𝑉 = 𝜌 × 𝐾𝑉

𝐷𝑉 = 1.06(4.13)

1 Pa ∙ s = 1,000 mPa ∙ s

𝐷𝑉 =

4.3778
1,000

𝐷𝑉 = 4.3778 mPa ∙ s
𝐷𝑉 = 4.4 𝑥 10−3 Pa ∙ s

Calculation of Control Shear Rate for Expressing Apparent Viscosity
The shear rate was calculated by dividing the velocity in m/s by the height the blood fell
from the top of the Zahn cup to the blood’s exit at the orifice. These measurements were
obtained from the instructions provided with the Zahn cup size two viscometer [20].
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Sample Calculation of Shear Rate
Calculation was done using the flow time of 15.18 seconds from the 25°C control trial.
𝑉𝑒𝑙𝑜𝑐𝑖𝑡𝑦 𝑜𝑓 𝐵𝑙𝑜𝑜𝑑 𝐹𝑙𝑜𝑤 =

ℎ𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑏𝑙𝑜𝑜𝑑 𝑓𝑎𝑙𝑙 (𝑚)
𝑓𝑙𝑜𝑤 𝑡𝑖𝑚𝑒 (sec)
𝑚

𝑣𝑒𝑙𝑜𝑐𝑖𝑡𝑦 ( )

𝑠
𝑆ℎ𝑒𝑎𝑟 𝑟𝑎𝑡𝑒 = ℎ𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑡ℎ𝑒 𝑧𝑎ℎ𝑛
𝑆ℎ𝑒𝑎𝑟 𝑟𝑎𝑡𝑒 =
𝑐𝑢𝑝(𝑚)

𝑉𝑒𝑙𝑜𝑐𝑖𝑡𝑦 =
3.3 𝑥 10−3
0.00274

0.0508
15.18

= 3.3 x 10-3 m/s

𝑆ℎ𝑒𝑎𝑟 𝑟𝑎𝑡𝑒 = 1.22 1/𝑠

Considerations for Result Interpretation
The data taken for the 0.09 M NaNO3, 0.10 M NaNO3, and 0.11 M NaNO3 are
represented as averages taken from the ten trials taken at 25°C and 37°C. The averages were
calculated while excluding major outliers. Outliers in this experiment are designated as any
values which were within a ± 0.20 separation of flow time data. Outliers were removed to
account for the human error caused from lifting the Zahn cup improperly or timing errors.
Human error was also minimized by repeating the runs ten times until values were repeated or
had very little deviation. Frequently, values will be compared to normal human blood viscosity

DYNAMIC VISCOSITY (PA ∙ S)

which is between 3.0 x 10-3 and 4.0 x 10-3 Pa ∙ s at 37°C [24].
0.005
0.004

In Figure 1, the control
y = -0.0002x + 0.008
R² = 0.7323

data was plotted as the

0.003

calculated DV versus the

0.002
0.001

Blood Rush Region

temperature. The trendline
obtained from the control curve

0
24 25 26 27 28 29 30 31 32 33 34 35 36 37 38
TEMPERATURE (C)

F I G U R E 1 . C O M P A R IS O N O F
V IS C O S IT Y A N D T E M P E R A T U R E FO R
CONTROL

was used to determine the
deviation of the sodium nitrate
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trials. This plot was also constructed in order to determine if the experimental model exhibited
the expected trend without a changed variable.
The data in Figure 1 exhibited the expected relationship between the viscosity of the
blood and the temperature. Turbulence in the sample was also observed in the control trials from
32°C to 37°C, as described in the literature. Between 31°C and 32°C, a dramatic decrease is

DYNAMIC VISCOSITY (PA ∙ S)

observed in the dynamic viscosity, which brings it to nearly 1 x 10-3 Pa∙ s below the range of
normal human blood viscosity.

0.005

y = -0.0405x + 0.0538
R² = 0.9113

0.004

From 32°C to 36°C, an increase

0.003

in dynamic viscosity is
0.002

observed; but it does not return

0.001

to the normal range of human

0
1.2

1.22

1.24
1.26
SHEAR RATE (1/S)

1.28

F I G U R E 2 . A P P A R E N T V IS C O S IT Y
C O M P A R IS O N FO R C O N T R O L

1.3

blood viscosity. Another dip is
seen from 36°C to 37°C. The

dynamic viscosity at 37°C lies below the range for normal human blood viscosity and is likely a
result of two factors. These factors are the lack of vessel-induced friction in the experimental
model and the blood rush phenomenon increasing shear stress (which is higher than the other
samples) and eddies in the blood samples. Figure 2 expresses the apparent viscosity through the
comparison of the dynamic viscosity and the shear rate of the blood flow for the control
temperatures. The trendline on this plot was used to evaluate deviations in further comparisons
of the trials employing sodium nitrate.
In Figure 3, each concentration of sodium nitrate is compared by apparent viscosity for
the 25°C trials. The minimum, maximum, and average for each concentration are depicted along
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with trendlines to express the turbulence of the blood samples. The 0.09 M NaNO3 had the

DYNAMIC VVISCOSITY (PA∙S)

highest viscosity range due to higher maximum, minimum, and average values. The trendline
does not include the average

0.006

y = -0.05x + 0.0655
R² = 0.9709
y = -0.0375x + 0.05
R² = 0.9985

0.005
0.004
0.003

0.09 M

marker, likely indicating that
0.10 M

this concentration of sodium
0.11 M

Normal Range

0.09 M
0.002

y = -0.0525x + 0.0686
R² = 0.9932

0.001

0.10 M

0.11 M

nitrate experienced some
turbulence. The R2 value for
the 0.09 M sample was

0
1.2

1.22

1.24

1.26

1.28

slightly lower than expected

SHEAR RATE (1/S)

FIGURE 3. APPARENT VISCOSITY FOR
VARYING CONCENTRATIONS OF SODIUM
NITRATE AT 25 °C

from the fits of the other two
concentrations, and the 0.10

M and 0.11 M showed better correlation to normal DV values for human blood. The trials
employing 0.10 M NaNO3 and the 0.11 M NaNO3 had similar ranges and averages, with little
deviation, and each trendline contains all three data points. The R2 values for these two
concentrations also indicate a strong correlation with blood flow and low turbulence. The 0.10 M
slope is steeper than that of 0.11 M NaNO3, with a slope more consistent to that of the 0.09 M
concentration. The averages for the 0.10 M and the 0.11 M concentrations fell within the range
for normal human blood viscosity. The ranges for the 0.10 M and 0.11 M trials were narrower
than that of the 0.09 M trial, with the 0.11 M having the narrowest range. The ranges for each of
the concentrations exceed the limits for normal human blood viscosity on the upper and lower
bound, but show linear trends indicating little to no turbulence in the blood samples.
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Table 2. Apparent Viscosity of Various Concentrations of NaNO3 at 25°C
Avg. Flow Time (s)

Avg. DV (Pa∙s)

Shear rate (1/s)

0.09 M NaNO3

15.12

4.2 x 10-3

1.22

0.10 M NaNO3

14.87

3.3 x 10-3

1.25

0.11 M NaNO3

14.93

3.5 x 10-3

1.24

In Table 2, the trends from Figure 3 are clearly defined. One can see from Figure 3 and
Table 2 that the 0.09 M sodium nitrate was the only concentration to lie outside of the normal
range for human blood viscosity at 25°C for both temperatures and the average. Table 2
illustrates the inverse relationship between the shear rate and the dynamic viscosity and clarifies
the averages seen in the 0.10 M and 0.11 M concentrations, which are tightly packed in Figure 3.
The average dynamic viscosity for the 0.10 M concentration of sodium nitrate is the lowest of
the three trials at 25°C, but it is still very close to the value calculated for the 0.11 M
concentration. The 0.10 M and 0.11 M concentrations are extremely close in values, while the
0.09 M concentration is slightly higher for each benchmark.
DYNAMIC VVISCOSITY (PA∙S)

0.006

0.09 M

y = -0.045x + 0.0592
R² = 0.9959

0.005
0.004

0.10 M
Normal Range

y = -0.0382x + 0.0509
R² = 0.9997
y = -0.0425x + 0.0564
R² = 0.9988

0.002
0.001
0
1.2

1.22

1.24
1.26
SHEAR RATE (1/S)

1.28

1.3

F I G U R E 4 . A P P A R E N T V IS C O S IT Y FO R
V A R Y IN G C O N C E N T R A T IO N S O F
S O D IU M N IT R A T E A T 3 7 ° C

viscosity is compared for each

0.11 M
0.09 M

0.003

In Figure 4, the apparent

0.10 M
0.11 M

concentration of sodium nitrate
at 37°C, the temperature chosen
to represent the warming phase
of induced hypothermia. The
minimum, maximum, and
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average for each concentration are depicted with trendlines to express the flow of the blood
samples. The 0.09 M concentration had a very narrow range, with nearly all points within the
normal range or without significant deviation. The 0.10 M concentration had more deviation
between its maximum and minimum, and only its maximum was within the normal range for
human blood viscosity. The 0.11 M concentration had the largest deviation in its range, but its
average was within the area for normal human blood viscosity. The maximum and average
portions of the ranges were within normal human blood viscosity for the 0.09 M and 0.11 M
concentrations. The minima for the 0.10 M and 0.11 M fell below the normal range for human
blood viscosity.
Table 3. Apparent Viscosity of Various Concentrations of NaNO3 at 37°C
Avg. Flow Time (s)
Shear rate (1/s)
Avg. DV (Pa∙s)
0.09 M NaNO3

15.03

3.8 x 10-3

1.23

0.10 M NaNO3

14.76

2.8 x 10-3

1.26

0.11 M NaNO3

14.93

3.5 x 10-3

1.24

In Table 3, the average values at 37°C are expressed to clarify between close values in
Figure 4. Table 3 shows that the 0.09 M and 0.11 M concentration were closer in average value
than the 0.10 M concentration. The 0.10 M concentration had the lowest dynamic viscosity and
was the only concentration that had an average below the normal value for human blood
viscosity.
In Figure 5, the average dynamic viscosities were plotted to show the change between 25
°C and 37°C for each of the concentrations of sodium nitrate and the control. The slopes of each
sample indicate whether the viscosity change was mediated during the warming of the blood.
The control sample had the largest variance in dynamic viscosity with a range from
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4.4 x 10-4 to 2.2 x 10-4 and a net change of 2.2 x 10-3. The 0.10 M NaNO3 had the next largest
0.005

DYNAMIC VISCOSITY (PA ∙ S)

Control
0.0045

0.09 M

y = -8E-06x + 0.0041
0.004

0.10 M

0.0035

0.11 M

y = 4E-19x + 0.0035

y = -5E-05x + 0.0047

0.003

Control
0.09 M

0.0025

0.10 M

y = -0.0002x + 0.009
0.002

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

0.11 M

TEMPERATURE (°C)

F I G U R E 5 . D Y N A M IC V IS C O S IT Y C H A N G E W IT H V A R Y IN G
C O N C E N T R A T IO N S O F S O D IU M N IT R A T E F R O M 2 5 ° C T O
37°C

change in dynamic viscosity over the two temperatures with a change of 6.0 x 10-4 which was
still much lower than the change seen in the control sample. This was the largest variance for the
sodium nitrate trials, and it ended with a dynamic viscosity that is not within the range of normal
human blood viscosity. The 0.09 M and 0.11 M concentrations show relatively little change over
the temperature range. The 0.09 M concentration had a net change of 1.0 x 10-4 and the 0.11 M
concentration showed no change. The 0.09 M and 0.11 M concentrations of sodium nitrate both
lie within the range for normal human blood viscosity at 25°C and 37°C.
In Table 4, the results of the graph are tabulated into calculations to more precisely
differentiate between the different trials at the two temperatures tested. The 0.09 M and 0.11 M
concentrations had a larger deviation in slope from the control with the values 1.92 x 10-4 and
1.99 x 10-4, respectively. A slightly smaller deviation was observed in the 0.10 M concentration
(1.50 x 10-4), but the value is still close to those of the 0.09 M and the 0.11 M concentrations.
At 25° C, the deviation for the 0.10 M concentration is larger than those for the 0.09 M and 0.11
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M concentration by a magnitude of 10. The 0.09 M and 0.10 M concentrations exhibit a smaller
change at the 25°C temperature, as shown by their higher values when cooled. Each of the
concentrations tested at the warmed temperature, 37°C, showed values of comparable magnitude
with little deviation from each other.

Table 4. Deviation of Dynamic Viscosity (DV) from the Control as the Samples were Warmed
Δ DV
Δ Slope
Δ DV at 25°C
Δ DV at 37°C
(Pa∙s)
(Pa∙s)
(Pa∙s)
(Pa∙s)
1.0 x 10-4

1.92 x 10-4

5.0 x 10-4

1.6 x 10-3

6.0 x 10-4

1.50 x 10-4

1.0 x 10-3

2.8 x 10-3

0.11 M NaNO3

0

1.99 x 10-4

9.0 x 10-4

1.3 x 10-3

Control

2.2 x 10-3

n/a

n/a

n/a

0.09 M NaNO3
0.10 M NaNO3

Analysis
The control curve displayed in Figure 1 exhibited the expected pattern of increased
viscosity at decreased temperature. At 32°C, variation seen in the viscosity illustrates
the turbulence in the sample, which was the focus of observation in the experiment. The
viscosities at 25°C and 37°C are out of the range of normal human blood viscosity, so the results
of the control are not optimal for comparison to the sodium nitrate trials. Therefore, slopes were
examined more closely for comparison. The steep decrease in dynamic viscosity may have been
caused by the lack of friction from the Zahn cup in comparison to a blood vessel.
The 0.09 M NaNO3 data showed some signs of mediation with a very small decrease in
dynamic viscosity between the 25°C and 37°C measurements. At both tested temperatures,
the dynamic viscosity for the 0.09 M NaNO3 stayed within the range of normal human blood
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viscosity. In comparison to the other trials, the 0.09 M concentration of sodium nitrate was the
second most effective at maintaining the constant viscosity during the warming of the blood.
The 0.10 M NaNO3 showed varied results, with a steeper decrease in dynamic
viscosity when the temperature was raised than those of the other two concentrations of sodium
nitrate. The dynamic viscosity at 25°C was within the range of normal human blood viscosity;
but over the warming process, the dynamic viscosity was lowered to below the normal range for
human blood viscosity. The dynamic viscosity for the 0.10 M NaNO3 was expected to lie
between the 0.09 M and 0.11 M concentrations of sodium nitrate when measured at 25°C, but it
did not. This inconsistency may indicate a possible error in the experimental model.
The 0.11 M NaNO3 expressed the greatest amount of mediation, with an unchanging
dynamic viscosity over the two temperatures tested. Both dynamic viscosity measurements
taken lie within the range for normal human blood viscosity. It is hypothesized that more nitric
oxide may be released for the higher concentrations of sodium nitrate, and that this may lead to
greater mediation. The 0.10 M NaNO3 did not follow the pattern of this hypothesis, but it may be
due to error in the 0.10 M NaNO3 trial.
There are limitations to this experiment, and they affected the results of the study. The
friction caused by the metal of the Zahn cup is much different than that friction caused by a
blood vessel. This limits the full potential of the blood reactivity to temperature to be realized, so
the inhibition may not be seen in a living organism. The Zahn cup is also not reactive
to vasodilation, which means the nitric oxide may have a very different result in vivo. Also,
the procedure in this experiment employed gravity to promote blood flow, whereas normal
circulation is propelled even against gravity. The experimental model also does not account for

Introduction of Sodium Nitrate to Affect Blood Viscosity

17

the presence of plaque in the circulatory system. Plaque would inhibit blood flow and would
likely be present in a patient undergoing IH. Finally, since the experiment was conducted ex vivo,
it cannot be known with certainty that this method is safe to conduct or if there are any adverse
effects to the treatment.
Human error was present in this experiment, due to the extensive amount of
multitasking and timing in order to conduct the experiment. When the data was analyzed, error
was assumed to have made the apparent viscosity values lower than they would be under normal
circulatory conditions. This is prominent in the control curve, which has values that lie outside of
the normal range of human blood viscosity.
The use of sheep blood itself may also account for several errors. One inconsistency may
be faster flow times due to the tightly packed structure of the sheep blood in comparison to
human blood [19]. This structure may also affect the amount of the nitric oxide bound to heme
groups in sheep blood. Examination of the blood samples under the microscope revealed that
more sheep red blood cells (SRBCs) were contained per unit area than in the human blood
samples collected. Sheep blood may also have a higher affinity for nitric oxide than human
blood, which could skew the results of the experiment; but this has not been addressed in
literature.
Degradation of the blood samples over time affected the extent of experimentation
and may have affected the results of the 0.10 M NaNO3 sample. The shelf life of the blood when
stored and properly cared for is approximately 28 days. However, it lasts longer when it is frozen
and treated with anticoagulants. The blood employed in this experiment was not frozen and was
defibrinated for testing purposes. This treatment may have degraded the RBCs more quickly than
expected. The 0.10 M concentration was the one concentration tested after the development of
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several changes in the procedure. The 0.10 M sample needed to be retested for consistency. It is
possible that the RBCs had denatured, causing faster flow than that seen in the other
concentrations. This risk of degradation limited the experimental time frame. Further testing with
fresh samples is needed to determine the answers to these questions.

Conclusion
In this experiment, sodium nitrate was investigated as a method to introduce nitric oxide
into the circulatory system of patients who are undergoing induced hypothermia. The viscosity of
the blood was measured in order to determine how the sodium nitrate would affect the flow rate.
In order to lower the mortality rate associated with induced hypothermia, the flow rate of the
blood as it is warmed would need to be slowed to avoid the effects of the blood rush. To
determine if sodium nitrate might be used to slow the flow rate of blood, viscosity was tested at
25°C and 37°C. This temperature range simulates the warming phase of induced hypothermia.
Each concentration of sodium nitrate was compared at these temperatures, to determine if the
turbulence was impeded.
Upon analyzing the data, the 0.11 M NaNO3 seemed the most effective at maintaining the
blood’s viscosity after raising the temperature. This concentration yielded concurrent viscosity
values for both temperatures. The 0.09 M concentration of NaNO3 also indicated some
mediation with a low amount of variation in dynamic viscosity as the blood was warmed. The
0.10 M NaNO3 did not seem to mediate as effectively as the other two samples tested. There was
a comparative disparity between the two temperatures, which more closely resembled the
untreated control. Neither the initial nor final temperature for the 0.10 M concentration was
found between the 0.09 M and 0.11 M concentration of sodium nitrate as they were expected to
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be. These odd results may have been caused from the degradation of the blood, a possible
experimental error that suggests further study.
Due to these results, no solid conclusions can be made as to whether sodium nitrate
mediated the effects of the blood rush during the warming process after induced hypothermia.
The skew seen in the 0.10 M NaNO3 trial’s data produced doubt as to whether the mediation
seen in the other nitrate trials were valid. This researcher believes that a correlation is present
that relates nitric oxide to a decreased blood flow due to an interaction between the hemoglobin
and bound nitric oxide [15]. The correlation seems likely because none of the trials produced
viscosity as low as that of the control at 37°C. Error from replicating the 0.10 M NaNO3 tests
close to the expiration date of the blood may have led to the degradation of the RBCs. This
degradation may have reduced the ability of the hemoglobin to interact with the nitric oxide and
could account for the decreased viscosities in this trial.
In order to verify that there is a correlation between decreased viscosity and intake of
nitric oxide, more experiments need to be done. The experimental design should be improved to
account for the human timing errors during the trials and to obtain more accurate results.
One of the major concerns for this experimental design is that the amount of nitric oxide
introduced into the blood is not known. It can only be assumed that higher concentrations of
sodium nitrate release more nitric oxide into the blood. In future experiments, the levels of
ornithine, citrulline, and arginine should be monitored in the blood before and after the addition
of nitric oxide to determine the relative release of nitric oxide in the blood [25]. Further
improvements can be made by testing each degree in the warming process from 32°C (the
recommended temperature for induced hypothermia) to 37°C at each concentration, to create a

Brianna Munnich & Dr. Willa Harper

20

better curve for correlation. The correlation between nitric oxide introduction and dynamic
viscosity might be better verified using only one concentration of nitric oxide to narrow the focus
of the experiment. Finally, a more precise viscometer should be used in future experiments, to
better model blood flow and reduce human error associated with the fast flow times. Much more
information could be gathered if the experiment were carried into a model more closely related
to the conditions in vivo.
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